1. Introduction {#sec1-biomolecules-10-00080}
===============

The extracellular matrix (ECM) is a three-dimensional network of extracellular macromolecules that provides structural and biochemical support to surrounding cells. More than a physical support tissue, the ECM is a dynamic structure that not only depends on but also regulates cell behavior and functions. Any change in its composition may reflect a disease state or may initiate a disease \[[@B1-biomolecules-10-00080],[@B2-biomolecules-10-00080],[@B3-biomolecules-10-00080]\]. Glycoproteins, collagens, and proteoglycans are the main components of the ECM, and they constitute the "core matrisome" encompassing almost 300 proteins in mammals. This matrisome contains 35 proteoglycans including small leucine-rich proteoglycans (SLRPs). The majority of SLRPs control ECM assembly by regulating collagen fibrillogenesis \[[@B4-biomolecules-10-00080],[@B5-biomolecules-10-00080],[@B6-biomolecules-10-00080]\]. In addition, SLRPs are able to control and interact with various cytokines in the extracellular space and bind to cellular receptors \[[@B7-biomolecules-10-00080],[@B8-biomolecules-10-00080],[@B9-biomolecules-10-00080],[@B10-biomolecules-10-00080]\].

In this review, the SLRP family's codon usage was investigated. The codon usage is commonly associated to pathological or stress conditions. In many coding sequences, the usage patterns of rare versus common synonymous codons are nonrandom and under selection pressure. Synonymous rare codons can enhance co-translational protein folding, increasing the likelihood of forming the native protein structure and suppressing alternatively folded structures \[[@B11-biomolecules-10-00080],[@B12-biomolecules-10-00080],[@B13-biomolecules-10-00080],[@B14-biomolecules-10-00080]\]. They increase the time available for post-translational chemical reactions to occur on specific residues upstream in the oriented sequence (N-terminal toward C-terminal), even before the protein translation is fully completed, adding an extra layer to the dynamic translational control \[[@B15-biomolecules-10-00080]\]. Here, the coding DNA sequence (CDS) of 17 SLRP proteins, for which the human CDS is known, were data-mined for their codon usage for seven amino acid residues deemed relevant to characterize the SLRP family.

Post-translational modifications are defined as the set of modifications that happen on the core protein such as the addition of a chemical group or the cleavage of a sequence of amino acid residues. The regulation of post-translational modifications was shown to play a role in the modulation of cell biological functions \[[@B16-biomolecules-10-00080]\]. There are more than 200 different types of post-translational modifications, the most common within SLRPs being glycanation, glycosylation, and enzymatic or oxidative degradation. Changes in SLRPs are associated with certain pathologies, and the pattern of these modifications could be used as a biomarker to diagnose diseases and predict their progression \[[@B6-biomolecules-10-00080],[@B9-biomolecules-10-00080]\].

This review describes the impact of the SLRP codon usage pattern and their post-translational modifications on the homeostasis of skeletal tissues. These two regulatory pathways are key cellular mechanisms for adaptation to stress and pathological conditions. Herein, the human skeletal system is defined as all the bony, ligamentous, fibrous and cartilaginous elements that together make up the skeleton and its attachment.

2. The SLRP Family: Classification and Structure {#sec2-biomolecules-10-00080}
================================================

Proteoglycans are complex macromolecules composed of a core protein covalently decorated by glycosaminoglycan (GAG) chains on serines or threonines. The small core protein has a molecular weight between 36 kDa and 77 kDa and is characterized by a variable number of central leucine-rich repeat (LRR) domains, each made of one α-helix and one β-strand. SLRPs are solenoid-like proteins with a horseshoe shape. Their concave face is formed of β-sheets, while the convex surface is formed of α-helices, where each LRR provides one β-sheet and one α-helix that correspond to one turn of the solenoid-like structure, the hydrophobic residues of the LRR facing inside. This structure is favorable to protein--protein interaction where the inner concave face is ideal to capture a ligand \[[@B17-biomolecules-10-00080],[@B18-biomolecules-10-00080],[@B19-biomolecules-10-00080]\] ([Figure 1](#biomolecules-10-00080-f001){ref-type="fig"}A). The consensus sequence of LRR is LXXLXLXXNXL, where L is a leucine, an isoleucine, a valine, or another hydrophobic amino acid; N is an asparagine; and X is any amino acid. LRRs are composed of variable amino acid sequences across the SLRP family, ranging in size from 20 to 29 residues, with 24 residues being the most representative \[[@B18-biomolecules-10-00080],[@B19-biomolecules-10-00080]\]. The N and C-terminal regions of the protein flanking the central LRR domain are rich in cysteine residues. The N-terminal domain contains four cysteines spaced by a varying number of amino acids. This N-terminal domain shows variability within the SLRP family. The cysteines present in this cluster form a disulfide bond between the first LRR and a β-hairpin. The C-terminal domain generally contains two cysteines \[[@B20-biomolecules-10-00080]\]. The C-terminal end includes the two C-terminal LRRs with the penultimate one called the ear-repeat. The ear-repeat is the longest LRR that is laterally extended from the main axis of the core protein to form the ear \[[@B18-biomolecules-10-00080],[@B19-biomolecules-10-00080]\] ([Figure 1](#biomolecules-10-00080-f001){ref-type="fig"}B). Ear-repeats are thought to be involved in ligand recognition and in the structural folding of the protein. As an example, a truncated decorin lacking C-terminal end residues is associated with congenital stromal corneal dystrophy. This mutated decorin is insoluble and retained in the cell, leading to an endoplasmic reticulum stress and an unfolded protein response \[[@B21-biomolecules-10-00080]\].

The SLRP family is composed of 18 members that have been classified into five distinct classes according to their structural and functional properties and their chromosomal organization. The five classes are divided into canonical and non-canonical classes. The presence of the ear-repeat is a feature of all the canonical SLRPs. The classes I--III (13 members) include the canonical SLRPs and the classes IV--V (5 members) include the non-canonical SLRPs \[[@B9-biomolecules-10-00080],[@B19-biomolecules-10-00080]\] ([Table 1](#biomolecules-10-00080-t001){ref-type="table"}).

Glycosaminoglycans (GAGs) are long linear polysaccharides made of repeated dissacharide units consisting of an amino sugar (N-acetylgalactosamine or N-acetylglucosamine) and an uronic acid (glucuronic acid or iduronic acid), on the basis of which they can be classified. They are synthetized through a complex enzymatic pathway starting from the addition of four monosaccharides (xylose, galactose, galactose, and glucuronic acid) on the hydroxyl group of a serine, except for the keratan sulfate (see below). This tetrasaccharide is the linker to which the different additional units are attached to form the diverse GAGs; additional diversity is generated through epimerization, sulfation, and deacetylation \[[@B22-biomolecules-10-00080]\]. Keratan sulfate addition results either from an N or an O-glycosylation via three different possible linkers, from which the chain elongation occurs. Interestingly, keratan sulfate might be associated with a tyrosine sulfation pattern, as the two coincide in the same SLRPs each time. GAG biosynthesis and modifications mainly take place in the Golgi apparatus \[[@B22-biomolecules-10-00080],[@B23-biomolecules-10-00080]\]. GAGs are subject to degradation within lysosomes where different enzymes such as exohydrolase and endoenzymes catabolize them to oligosaccharides with further desulfation steps \[[@B24-biomolecules-10-00080],[@B25-biomolecules-10-00080]\].

Many GAG side chains may be attached to SLRP core proteins, mainly to the N-terminal part. These GAG modifications are often similar for an SLRP class and therefore can be used for their characterization ([Table 1](#biomolecules-10-00080-t001){ref-type="table"}). GAG chains are involved in the structure, the conformational stability, Ref. \[[@B26-biomolecules-10-00080]\] and the secretory process of SLRPs \[[@B27-biomolecules-10-00080]\].

3. SLRP Codon Usage Patterns May Fine-Tune Selective Translation Pathways during Cellular Stress Conditions {#sec3-biomolecules-10-00080}
===========================================================================================================

The SLRP family members share common structural features as described in the classification and structure section and partially illustrated in [Table 1](#biomolecules-10-00080-t001){ref-type="table"}. Here, we conducted a biostatistical and bioinformatics exploratory analysis of the SLRP family members based on the codon usage of the genes encoding 17 members of the family.

Biases in codon usage have been documented to play a role in the translational fine-tuning of protein expression levels for cells undergoing stress conditions. This fine-tuning involves enzymatic modifications (i.e., reprogramming) of specific t-RNAs on their U34 wobble-base \[[@B59-biomolecules-10-00080]\]. These t-RNA U34 wobble-base modifications affect the elongation rate during translation for transcripts that have a specific pattern of codon usage, resulting in a selective increase in the translation of specific proteins by the cytoplasmic pool of ribosomes. A well-known example \[[@B60-biomolecules-10-00080]\] is the modified U34 wobble-base called mcm^5^-s^2^-U34 (methoxy-carbonyl-methyl-5, thio-2 uridine 34), which is catalyzed by three successive enzymes targeting the original uridine t-ribonucleobase (U34-t-RNA): acetyltransferase elongator (Elp1-6), methyltransferase TRM9-like domain of alkylation repair homolog (ALKBH8), and the cytosolic thiouridylase homolog 1 and 2 (Ctu1/2). This modified t-RNA mcm^5^-s^2^-U34 wobble-base will eventually base pair to the transcript cognate codons whose third base ends preferentially with an A instead of a G, thus resulting in a privileged base pairing with the rarely used codons for lysine, glutamine, and glutamate.

In yeasts, this mechanism has been shown to enhance the translation of proteins involved in hypoxic stress responses \[[@B61-biomolecules-10-00080]\]. In melanoma cancer cells, it has been shown to enhance the expression of HIF1-α and of other proteins enriched in the codon usage patterns that happen to be promoted in tumor cells resistant to targeted therapy \[[@B62-biomolecules-10-00080]\].

Even in the absence of enzymatic tRNA modifications, the usage of rare codons may be required to slow down the translating ribosome to increase the available time for proper folding of the nascent protein or to increase the likelihood of chemical additions (e.g., hypothetical glycanation tagging) on specific residues located upstream in the sequence being translated for later post-translational purposes.

The coding DNA sequences (CDS) of 17 SLRP proteins (n = 17 observations) were data-mined for their codon usage of seven amino acid residues deemed relevant to characterize the SLRP family: cysteine (C:Cys), lysine (K:Lys), glutamine (Q:Gln), glutamate (E:Glu), asparagine (N:Asn), aspartate (D:Asp), and of course leucine (L:Leu). The genetic code degeneracy associated to these amino acid residues reads as follows: cysteine, two codons: UGC, UGU; lysine, two codons: AAA, AAG; glutamine, two codons: CAA, CAG; glutamate, two codons: GAA, GAG; asparagine, two codons: AAU, AAC; aspartate, two codons: GAU, GAC; and finally leucine, six codons: UUA, UUG, CUA, CUC, CUG, and CUU. The subset of all these investigated codons contains 18 codons (p = 18 variables).

The coding DNA sequences (CDS) of 17 members of the SLRP family (all SLRP members except the class I protein ECMX, whose CDS sequence was not found) were extracted from the Ensembl human genome repository (GRCh38.p12 assembly) in FASTA format. The complete coding sequences were collected with the longest possible open reading frame (ORF) starting from start codon AUG and ending at the most downstream occurrence of one of the three possible stop codons (UAA, UAG, UGA). We processed each sequence to count the total number of codons in the longest open reading frame, to count the codon usage of the seven aforementioned amino acid residues and to compute the codon usage frequencies of the corresponding 18 codons under investigation with a home-made Python program using BioPython modules (importing SeqIo, IUPAC, codonTable and suffix trees). The data were exported and then retrieved in R for further statistical analysis. The codon frequencies revealed different bias patterns in codon usage between the SLRP family members, on which an unsupervised statistical learning analysis was performed \[[@B63-biomolecules-10-00080]\]. The results of the principal component analysis (PCA) are presented below. The PCA was conducted with the prcomp function in R and graphically represented with the biplot function in R (both functions in software package 'stats' in R version 3.5.2. R Core Team, 2014. <https://www.r-project.org/>). [Figure 2](#biomolecules-10-00080-f002){ref-type="fig"} displays the percentage of the variance that is explained by the principal components (PCs). The first two PCs explain 60.08% and 10.53% of the variance, while together they explain more than 70.6% of the data variance.

In a graphical representation, orthogonal loading vectors tend to be less correlated with each other than co-linear or almost co-linear loading vectors (vectors pointing in the same, or opposite direction), which are interpreted as highly correlated variable features.

The biplot on [Figure 3](#biomolecules-10-00080-f003){ref-type="fig"} displays a 2D representation of the scores for the 17 protein members from the SLRP family (in black) projected along the first two principal components and a representation of the 18 loading vectors for the codon usage features (red arrowed vectors). It shows that the SLRP family mainly clusters in two groups and that osteomodulin and nyctalopin appear as outlying members of the SLRP family. There seems to be at least two clusters with different codon usage patterns. In cluster 1 (left part of the biplot), the chondroadherin (CHAD), biglycan (BGN), Prelp (PRELP), fibromodulin (FMOD), opticin (OPTC), tsukushi (TSK), podocan (PODN), podocan like protein 1 (PDNL), and nyctalopin (NYX) mature mRNA transcripts all present a similarly biased codon usage pattern represented in [Table 2](#biomolecules-10-00080-t002){ref-type="table"}. Cluster 2 (right part of the biplot) is made of decorin (DCN), lumican (LUM), epiphycan (EPN), asporin (ASP), ECM2, osteoglycin (OGN), keratocan (KTN) and osteomodulin (OMD). Its codon usage pattern contrasts with that of cluster 1 and is represented in [Table 2](#biomolecules-10-00080-t002){ref-type="table"}.

In Cluster 2, it is noted that osteomodulin appears to have a strong codon usage bias. Indeed, leucine (L), in addition to CUU, is significantly encoded by the rare CUA, and the three K, Q, and E amino acid residues are mostly encoded by the unusual codons ending with the AA dinucleotide. Thus, their codon usage is strongly biased toward the A-ending codons, which are known to preferentially base pair with the modified mcm^5^s^2^--U34 tRNA. Therefore, we suspect that the osteomodulin protein translation rate would be enhanced in cells undergoing hypoxic stress or mechanical stress via enzymatic reprogramming of the wobble U34 in the cognate t-RNA decoding leucine, glutamine, glutamate, and lysine residues. [Supplementary Figures S1 and S2](#app1-biomolecules-10-00080){ref-type="app"} show the codon usage biased patterns contrasting osteomodulin with the other members of the SLRP family for leucine and for the triplet glutamine, glutamate, and lysine amino acids residues.

Due to a similar though less extreme codon usage bias, it is hypothesized that asporin, osteoglycin, keratocan, and ECM2 could also have their translation rate enhanced in cellular stress conditions. The occurrence of re-programming of the wobble-base U34 tRNA under stress conditions has not yet been checked experimentally in the context of skeletal or cartilaginous tissues. Experimental validation is required to investigate whether this cascade of events results in differential levels of protein expression in the SLRP family under cellular stress conditions.

4. Roles of SRLP GAG Moieties in Fibrillogenesis {#sec4-biomolecules-10-00080}
================================================

A major feature of the SLRPs is their interaction with collagen fibrils in the ECM. Although they bind through their core protein, their GAGs are also functional actors. GAG moieties were shown to interact directly with collagen and to modulate their fibrillogenesis \[[@B64-biomolecules-10-00080],[@B65-biomolecules-10-00080]\]. High-resolution scanning electron microscopy indicates that these interactions are periodic and GAG chains bound to the collagen surface can form interfibrillar elastic bridges and belts around fibrils. GAGs regulate the fibril diameter and the interfibrillar spacing, and they also assemble the collagen fibrils, thus generating a network that organizes the ECM \[[@B64-biomolecules-10-00080],[@B66-biomolecules-10-00080],[@B67-biomolecules-10-00080],[@B68-biomolecules-10-00080]\]. In the interfibrillar space, a majority of GAGs is oriented spanning adjacent fibrils, while also interacting together to form antiparallel structures called "shape modules" and keeping collagen fibrils at defined distances \[[@B66-biomolecules-10-00080],[@B69-biomolecules-10-00080],[@B70-biomolecules-10-00080],[@B71-biomolecules-10-00080]\].

Data from in vivo studies also suggest collagen fibril regulation through the presence of GAGs. The glycanation of decorin plays a critical role in the early stages of fibrillogenesis and reduces the collagen fibril diameter. In Ehlers--Danlos syndrome, the decrease of galactosyltransferase activity impairs the glycanation of decorin and biglycan, and collagen fibrillogenesis is decreased \[[@B72-biomolecules-10-00080],[@B73-biomolecules-10-00080],[@B74-biomolecules-10-00080]\]. In contrast, decorin dermatan sulfate-deficient knock-in mice, where the site of GAG attachment was mutated, fail to express any variation of the collagen fibril diameter. Although we cannot exclude compensation by other SLRPs associated with dermatan sulfate in the mouse model or the lack of functional conservation of GAGs between human and mouse \[[@B75-biomolecules-10-00080]\], this discrepancy indicates that more studies are required to clarify the role of SRLPs' GAG chains.

A model has been proposed in which GAG bridges could manage mechanical stress, namely occurring in tendons that are biological structures transmitting large forces between muscles and bones. GAG bridges are supposed to play a role in force control through fibril-to-fibril interactions during loading. In addition, decorin enhances mechanical properties by reducing fibrils aggregation during polymerization \[[@B76-biomolecules-10-00080]\]. Therefore, SLRPs could protect collagen fibrils against excessive mechanical strains \[[@B77-biomolecules-10-00080],[@B78-biomolecules-10-00080],[@B79-biomolecules-10-00080],[@B80-biomolecules-10-00080]\]. However, this model is subject to controversy. Indeed, several studies have found that the enzymatic removal of GAGs did not affect the mechanical properties of collagen fibrils \[[@B71-biomolecules-10-00080],[@B81-biomolecules-10-00080],[@B82-biomolecules-10-00080],[@B83-biomolecules-10-00080]\] except for pathological post-injury tendons \[[@B84-biomolecules-10-00080]\]. Controversially, another investigation of the collagen mechanical response in both native and GAG-depleted tendons in mouse proposed a model where GAGs promote the fibrils sliding under straining conditions by isolating individual fibrils to bear the load \[[@B85-biomolecules-10-00080]\]. This conflicting evidence leaves the question open about the complex functions of the GAG and SLRP extrafibrillar network in ECM assembly.

Besides direct interaction and fibril organization, GAGs have a protective role. When SLRPs are bound to collagen fibrils, their GAGs protect collagen fibrils in acidic conditions against cathepsin K, conferring on them putative functions during bone resorption \[[@B86-biomolecules-10-00080]\].

5. SLRP GAG Moieties: Fingerprints of the Tissue Status and Active Players {#sec5-biomolecules-10-00080}
==========================================================================

The diversity of SLRP's GAG moieties is a characteristic of the tissue and can serve to track its status. Furthermore, the same SLRP displays different forms via the absence or presence and diversity of its GAGs.

In articular cartilage, intervertebral disc, and dental tissue, biglycan and decorin may be represented under a proteoglycan or a non-proteoglycan form \[[@B87-biomolecules-10-00080],[@B88-biomolecules-10-00080],[@B89-biomolecules-10-00080]\]. Immunoblots before and after the removal of glycanation have revealed two forms of biglycan lacking GAG whose abundance is low in juveniles in the articular cartilage and in the intervertebral disc but increases in adults until they become predominant. The abundance of the biglycan proteoglycan form appears to be stable through life \[[@B87-biomolecules-10-00080],[@B88-biomolecules-10-00080]\]. However, for decorin, its non-proteoglycan form is always a minor component, even though there is also an increase related to age \[[@B88-biomolecules-10-00080]\]. In cortical bone, the level of decorin glycanation decreases with age \[[@B90-biomolecules-10-00080]\]. Finally, the decorin GAG length is reduced in the tendon fascicle of old mice \[[@B91-biomolecules-10-00080]\].

The glycanation of fibromodulin is modified by aging, similar to decorin and biglycan. The proteoglycan form is present in juvenile human articular cartilage, and the GAG chains are shortened through the aging process until they are mostly represented by the non-proteoglycan form in mature cartilage. However, fibromodulin continues to be substituted with N-linked oligosaccharide \[[@B92-biomolecules-10-00080]\].

It appears that lumican, a keratan sulfated SLRP, goes through the same age-related mechanism in human articular cartilage. The increased representation of the non-glycanated form of lumican is due to a lack of keratan sulfate synthesis by mature chondrocytes. It is interesting to point out that aggrecan conserves its keratan sulfate chains in mature cartilage, demonstrating that chondrocytes are still able to synthesize \[[@B93-biomolecules-10-00080],[@B94-biomolecules-10-00080]\]. In human cultured chondrocytes, it was shown that growth factors/cytokines were able to modulate the GAG chain length and sulfation of lumican by regulating the cell metabolism. IL-1β induces the production of a non-glycanated lumican, whereas the length of GAG chains in glycanated forms is modulated by basic fibroblast growth factor (bFGF), insulin growth factor (IGF)-1, and transforming growth factor (TGF)β \[[@B95-biomolecules-10-00080]\].

Osteomodulin presents a different pattern of changing glycosylation profiles among keratan sulfated SLRPs, in that it varies through endochondral bone formation and its biomineralization process. In non-mineralized ECM, osteomodulin is non-glycanated and N-glycosylated, whereas in mineralized ECM, the keratan sulfate modification of osteomodulin increases with bone maturation \[[@B96-biomolecules-10-00080]\].

It was suggested that the changes in growth factor/cytokine synthesis with aging could be one mechanism explaining the post-translational GAG modifications of SLRPs \[[@B95-biomolecules-10-00080]\]. Non-glycanated SLRPs can also result from the degradation of a glycanated precursor, as demonstrated by the N-terminal sequence analysis of SLRPs coming from intervertebral disc tissue \[[@B87-biomolecules-10-00080]\].

In addition to the presence or absence of glycanation, the nature of the GAG chains substituted to the SLRP core is also changing during bone development, and therefore could be associated with different functions. In cultured alveolar bone cells, biglycan is conjugated mainly with dermatan sulfate during the cell proliferation phase and switches to only chondroitin sulfate chains during the mineralization phase. Similarly, decorin carries many dermatan sulfate chains during early bone matrix formation but later associates only with chondroitin sulfate during mineralization \[[@B97-biomolecules-10-00080]\]. The same changing profiles occur in dental tissue, where in the predentine, biglycan and decorin are mostly associated with dermatan sulfate, whereas in the predentine/dentine interface, the chondroitin sulfate becomes predominant, and in the dentine itself, it is the only GAG chain identifiable \[[@B89-biomolecules-10-00080]\], while keratan sulfate distribution in the predentine forms a gradient with a maximum toward the mineralization front \[[@B98-biomolecules-10-00080]\]. Moreover, the position of the sulfate within the GAG also varies within these tissues, and the GAG length is longer in the dentine than in the predentine and in the dentine/predentine interface \[[@B89-biomolecules-10-00080]\]. Interestingly, GAG components are active players in the mechanical properties of the dental tissues such as stiffness and ductility due to their physicochemical properties, their location, and also by modulating the collagen structure through interfibrillar bridges. GAGs are key factors in the dentin's ability to recover under strain and deformation events in a time-dependent manner and contribute to the dental tissues' longevity and conservation of their mechanical integrity. GAGs are also thought to play a role in the mineralization; in dentine, chondroitin sulfate may allow the mineralization process through sequestering calcium ions. These mechanisms might be displayed in other mineralized tissues \[[@B99-biomolecules-10-00080],[@B100-biomolecules-10-00080],[@B101-biomolecules-10-00080],[@B102-biomolecules-10-00080],[@B103-biomolecules-10-00080]\].

The nature of the GAG can also help to discriminate a tissue, e.g., decorin and biglycan are mostly associated with dermatan sulfate in the annulus fibrosus, but with chondroitin sulfate in the cartilage end-plate \[[@B87-biomolecules-10-00080]\]. Moreover, the modifications occurring on SLRPs could be used to assess the differentiation stage of cells. In C2C12 mouse cells treated with the bone morphogenetic protein (BMP)-2, modifications to the decorin GAG chains' length take place during the differentiation from myoblast to osteoblast. In addition to being upregulated, decorin has longer GAG chains in induced cells \[[@B104-biomolecules-10-00080]\].

Defective glycanation is correlated with pathological states, for instance in gerodermia osteodysplastica. In the organism model corresponding to this pathology characterized by the early onset of osteoporosis, decorin and biglycan are glycanated to a lesser extent, and it is suggested that this defect is involved in the abnormal gain of periosteum thickness \[[@B90-biomolecules-10-00080]\]. Equine degenerative suspensory ligament desmitis (DSLD), which affects tendons, ligaments, and other connective tissues and resembles Ehlers--Danlos syndrome, correlates with the accumulation of decorin carrying abnormally glycosylated GAG chains \[[@B105-biomolecules-10-00080]\]. In this case, chondroitin sulfate replaces the normal dermatan sulfate, and this modification leads to a reduced TGF-β1 binding affinity and the production of antibodies against decorin. There is no change in the level of dermatan sulfate epimerase, the enzyme in charge of the dermatan sulfate synthesis; however, in DSLD, the tendon is associated with high levels of BMP-2, which may enhance proteoglycan production \[[@B106-biomolecules-10-00080],[@B107-biomolecules-10-00080]\].

Furthermore, ECM assembly may be influenced by post-translational modifications affecting molecular interactions. These interactions in turn may regulate signaling pathways. The GAG chains of biglycan enhance the binding of calvarial osteoblastic cells from mouse to BMP-4. Consequently, the signaling pathway is more strongly activated, with an increased phosphorylation of Smad 1/5/8 and upregulation of a set of osteoblastic markers such as Cbfa1 (Runx2), osteopontin, bone sialoprotein (BSP) and osteocalcin. Therefore, biglycan plays a role in osteoblast differentiation as a cytokine reservoir thanks to its GAG chains \[[@B108-biomolecules-10-00080]\]. Biglycan GAGs also play a crucial role on the Erk pathway promoting osteoblast differentiation, as no phosphorylation of Erk is observed when murine pre-osteoblasts are treated with biglycan lacking GAGs \[[@B109-biomolecules-10-00080]\]. It is conceivable that the age-related evolution of SLRP GAGs is correlated with their balancing function on growth factors as, in juveniles, the osteoblast differentiation process needs to be active and fully functional \[[@B108-biomolecules-10-00080]\]. Surprisingly, a study showed that although all forms of biglycan positively affect BMP-2 signaling in C2C12 myogenic cells, even if non-glycanated forms are more efficient, only the biglycan lacking GAG induces osteogenesis in a rat mandible-deficient model. The studies concluded that the biglycan positive effect on BMP-2 is inhibited by its GAG moieties. However, it is important to highlight that the cells in these studies are not at the same differentiation stages nor the same cell lines, but a role of GAGs dependent on the type of BMP cannot be excluded \[[@B108-biomolecules-10-00080],[@B110-biomolecules-10-00080],[@B111-biomolecules-10-00080]\].

6. Other SLRP Post-Translational Events in Skeletal Tissues {#sec6-biomolecules-10-00080}
===========================================================

6.1. Sulfation {#sec6dot1-biomolecules-10-00080}
--------------

Sulfated tyrosines were identified in fibromodulin, osteomodulin, lumican, and opticin \[[@B38-biomolecules-10-00080],[@B112-biomolecules-10-00080]\]. The tyrosine sulfate domain of SLRPs is interacting with proteins, mimicking heparin via the highly negative charge produced in combination with acidic amino acids. Fibromodulin and osteomodulin were shown to bind heparin-binding protein through this specific domain, and the affinity varies via the sulfated tyrosine residues number and their position. When present on the fibromodulin N-terminal domain, it attracts the MMP-13 protease and guides the cleavage of the domain \[[@B113-biomolecules-10-00080],[@B114-biomolecules-10-00080]\]. This specific domain is involved in the fibrillogenesis process. Fibromodulin can bind to collagen type I by both its LRR and its N-terminal tyrosine sulfated domain, which allows it to interact simultaneously with two collagen molecules. That feature may be useful in the assembly and networking of the ECM. The sulfated domain affects the collagen fibril formation and induces a shortened lag phase, thus affecting the arrangement of collagen molecules into highly organized fibrils structures \[[@B115-biomolecules-10-00080]\].

6.2. SLRP Degradation and Cleavage in Skeletal Tissues {#sec6dot2-biomolecules-10-00080}
------------------------------------------------------

In addition to their glycosylation and glycanation, SLRPs degradation interferes with their biological functions and adds a level of complexity to their network. In this part, we will discuss the degradation mechanisms of SLRPs and the impact on their biological functions.

Several MMPs have been recognized to cleave SLRP members in vitro. MMP-2, MMP-3, and MMP-7 can cleave the human recombinant decorin. Interestingly, MMP-2 and MMP-3 show decreased efficiency when decorin is lacking its GAG. The consequences of substrate affinity variation with respect to post-translational modification combined with the increase of non-glycanated forms through aging remains unclear \[[@B116-biomolecules-10-00080]\]. Membrane-type matrix metalloproteinase-1 (MT1-MMP) can induce cleavage of the human recombinant lumican \[[@B117-biomolecules-10-00080]\]. Fibromodulin is cleaved in the N-terminal region containing sulfated tyrosine when cartilage degradation is induced. MMP-13 can cleave fibromodulin in the region interacting with collagen fibrils \[[@B113-biomolecules-10-00080],[@B118-biomolecules-10-00080]\]. MMP-13 is also able to cleave biglycan, opticin, and to a lesser extent, lumican and decorin. In the latter cases, the degradation products are of low abundance despite proven direct interaction between MMP-13 and decorin \[[@B119-biomolecules-10-00080],[@B120-biomolecules-10-00080],[@B121-biomolecules-10-00080]\]. In human cartilage, MMP-1-2-3-7-8-9 were shown to be part of opticin catabolism with different proteolytic efficiencies, with MMP-2 and MMP-7 being the most efficient \[[@B122-biomolecules-10-00080]\]. MMP-9 and MMP-12 can cleave biglycan, and the fragments produced appear to be relevant neo-epitopes associated with dysregulated ECM remodeling pathogenesis. Indeed, the biglycan fragments were increased in ex vivo degraded cartilage explants and in the serum of a rheumatoid arthritis (RA) rat model \[[@B123-biomolecules-10-00080]\]. In addition to the MMPs, ADAMTS-4, ADAMTS-5, and granzyme B can be mentioned as efficient enzymes that cleave some SLRPs, as it was proven for biglycan, decorin, and opticin \[[@B122-biomolecules-10-00080],[@B124-biomolecules-10-00080],[@B125-biomolecules-10-00080],[@B126-biomolecules-10-00080]\]. Chondroadherin can be digested by the serine protease HTRA1 in degenerated human intervertebral discs \[[@B127-biomolecules-10-00080]\].

The various locations of the cleavage sites lead to numerous possibilities of SLRP fragments to be produced ([Table 3](#biomolecules-10-00080-t003){ref-type="table"}). For instance, biglycan is processed in its N-terminal region \[[@B88-biomolecules-10-00080],[@B128-biomolecules-10-00080]\] within its core, namely in its fifth LRR by ADAMTS-4 and ADAMTS-5 \[[@B124-biomolecules-10-00080]\] and in its C-terminal region by MMPs \[[@B119-biomolecules-10-00080]\]. The biological importance of this large variety of fragments remains an under-examined field and needs further research.

Corroborating the in vitro data, there is evidence that SLRPs are degraded in vivo. During the aging process, decorin and biglycan undergo degradation in bovine tendons \[[@B130-biomolecules-10-00080]\]. Degraded biglycan, lumican, keratocan, and opticin fragments were found in human articular cartilage, while decorin and fibromodulin fragments were found in remodeling tissues from ovine intervertebral discs after a lesion \[[@B119-biomolecules-10-00080],[@B120-biomolecules-10-00080],[@B131-biomolecules-10-00080]\]. The team of Zhen et al. *(2008)* \[[@B132-biomolecules-10-00080]\] characterized several MMPs and ADAMTS that carry out the proteolysis of SLRPs; among them were biglycan, decorin, fibromodulin, osteoglycin, and PRELP. They showed that in human cartilage, biglycan, fibromodulin, and PRELP are cleaved by MMP-2, MMP-3, MMP-8, MMP-9, MMP-12, MMP-13, ADAMTS-4, and ADAMTS-5. Decorin can be digested by the same proteases except for MMP-9, lumican by MMP-12 and ADAMTS-4, and osteoglycin by MMP-2, MMP-8, and ADAMTS-4 \[[@B132-biomolecules-10-00080]\]. The processing of SLRPs occurs in human knee, hip articular cartilage, and meniscus, as it was shown for decorin, biglycan, lumican, and keratocan. This fragmentation process is increased in tissues undergoing degradation, and there is a slight increase related with the aging process but not in every tissue. However, fewer fragments were found in tissues for fibromodulin. Interestingly, but not unexpectedly, fragments observed after in vitro cleavage of biglycan and decorin by MMP-13 correspond to the fragments characterized in vivo, in contrast to the fibromodulin fragments. Yet, it must be highlighted that a majority of the in vivo, so-called naturally occurring fragments do not correlate with fragments generated in vitro. This suggests that besides all the enzymes already identified to cleave the SLRPs, additional unknown enzymes may be involved in their degradation \[[@B119-biomolecules-10-00080],[@B133-biomolecules-10-00080],[@B134-biomolecules-10-00080]\].

This phenomenon may lead to the alteration of ECM homeostasis and its biomechanical properties, and hence damage skeletal tissues over time \[[@B119-biomolecules-10-00080],[@B124-biomolecules-10-00080],[@B133-biomolecules-10-00080],[@B135-biomolecules-10-00080],[@B136-biomolecules-10-00080]\]. An increased proteolysis of chondroadherin has also been observed in the scoliotic disc of some adolescent patients and in adult degenerative discs when compared to normal discs. The fragmentation of chondroadherin is also characteristic of the disease, the cleavage site-specific for disc degeneration is represented in [Table 2](#biomolecules-10-00080-t002){ref-type="table"}, making the chondroadherin fragment an efficient biomarker \[[@B127-biomolecules-10-00080],[@B137-biomolecules-10-00080]\]. In addition, other SLRPs present enhanced fragmentation patterns in pathological human and canine intervertebral discs \[[@B138-biomolecules-10-00080],[@B139-biomolecules-10-00080],[@B140-biomolecules-10-00080]\].

Interestingly, the SLRP fragment pattern has been characterized in serum of osteoarthritic (OA) and RA patients and in the serum of animals with experimentally induced OA. This observation indicates a relationship between these pathologies and the SLRP degradation. The fragmentation pattern is more than a global OA feature; it is also specific to the SLRP member and the joint localization. For example, more cleavage products are detected in OA hip than in OA knee articular cartilage for decorin, biglycan, lumican, and keratocan \[[@B133-biomolecules-10-00080],[@B136-biomolecules-10-00080],[@B141-biomolecules-10-00080]\]. The extent of fibromodulin and opticin degradation by MMP-13 is correlated with the severity of the cartilage damage \[[@B113-biomolecules-10-00080],[@B119-biomolecules-10-00080],[@B120-biomolecules-10-00080],[@B142-biomolecules-10-00080]\]. Knowing that almost all the members of the SLRP family are involved in collagen interaction as previously reviewed by Chen and Birk, 2013 \[[@B6-biomolecules-10-00080]\], and that they have a protective function on collagen fibrils, their degradation could lead to the exposure of the MMP-13 cleavage site on the collagen, indicating a predisposition for the initiation of cartilage damage \[[@B113-biomolecules-10-00080],[@B118-biomolecules-10-00080],[@B119-biomolecules-10-00080],[@B120-biomolecules-10-00080]\]. Consolidating this hypothesis, it was demonstrated that the maximal biglycan processing in the medial meniscus outer zone is concomitant with collagenolysis \[[@B126-biomolecules-10-00080],[@B143-biomolecules-10-00080]\]. Moreover, treatment with RS 110--2481, an MMP-13 inhibitor, prevents not only SLRP degradation but also collagenolysis \[[@B119-biomolecules-10-00080],[@B144-biomolecules-10-00080]\]. The loss of SLRPs weakens the cartilage's mechanical properties \[[@B119-biomolecules-10-00080],[@B136-biomolecules-10-00080]\].

It appears that SLRP fragments are of interest to unravel the mechanism of OA, and some could be specifically beneficial to study. High levels of biglycan were found in synovial fluid, which is located in the joint cavities of OA and RA patients \[[@B145-biomolecules-10-00080],[@B146-biomolecules-10-00080]\]. Treatments with soluble biglycan were reported to induce an inflammatory response in human chondrocytes through TLR-4 and NF-κB activation, enhancing the catabolic response in cartilage explants depending on their OA stage \[[@B146-biomolecules-10-00080],[@B147-biomolecules-10-00080]\]. It was also demonstrated that cartilage neo-angiogenesis associated with inflammation \[[@B148-biomolecules-10-00080]\] is related to the degradation of opticin, which is an inhibitor of angiogenesis, by regulating the adhesiveness of endothelial cells. In OA cartilage, opticin is a substrate for several proteases, and particularly MMP-7 \[[@B120-biomolecules-10-00080],[@B122-biomolecules-10-00080],[@B149-biomolecules-10-00080]\].

The cleavage of SLRPs also impacts the accumulation of growth factors in the ECM. SLRPs are known to bind several growth factors, such as TGF-β, FGF, and BMP, and block their biological activity \[[@B150-biomolecules-10-00080]\]. Direct evidence of active TGF-β1 being released from decorin and biglycan upon cleavage by granzyme B, a protease that accumulates in the extracellular space during inflammation, was demonstrated. TGF-β1 was also released from decorin after proteolysis by MMP-2, MMP-3, or MM-7. Biglycan, asporin, and fibromodulin were also found to bind TGF-β, giving them the possibility to release it when cleaved \[[@B151-biomolecules-10-00080],[@B152-biomolecules-10-00080]\]. Moreover, in SLRP knockout mice, there is an excessive activation of TGF-β1 signaling, leading to an impaired control on osteoprogenitor cells and chondrogenesis. These data suggest a mechanism by which the modulation of the bioavailability of cytokines such as TGF-β1 can correlate to the development or even the initiation of OA \[[@B8-biomolecules-10-00080],[@B116-biomolecules-10-00080],[@B125-biomolecules-10-00080],[@B153-biomolecules-10-00080]\].

6.3. SLRP Intracellular Degradation Pathways {#sec6dot3-biomolecules-10-00080}
--------------------------------------------

The intracellular catabolism requires the lysosomal system, and SLRPs can accumulate within cells when lysosomes are inhibited \[[@B129-biomolecules-10-00080],[@B154-biomolecules-10-00080],[@B155-biomolecules-10-00080],[@B156-biomolecules-10-00080],[@B157-biomolecules-10-00080],[@B158-biomolecules-10-00080]\]. This mechanism appears to be partially competitive between SLRPs. The internalizing process is receptor-mediated, and the core protein involving the LRR structure is the ligand for the putative 51kDa and 26 kDa human receptors of endocytosis located at the plasma membrane and in the endosomal compartment. Furthermore, the presence of GAG modification adds a supplemental layer of control, as its presence negatively affects the uptake \[[@B159-biomolecules-10-00080],[@B160-biomolecules-10-00080],[@B161-biomolecules-10-00080],[@B162-biomolecules-10-00080],[@B163-biomolecules-10-00080]\]. Interactions between SLRPs and other ECM proteins also interfere with the endocytosis, as only free SLRPs are degraded through the internal pathway \[[@B164-biomolecules-10-00080]\]. Additional human receptors possibly involved in endocytosis were later characterized in a different cell type for decorin or biglycan, suggesting redundancy in receptors involved in SLRP endocytosis. The putative receptors encompass the first discovered 51 kDa and 26 kDa \[[@B159-biomolecules-10-00080]\]; a 110 kDa receptor \[[@B165-biomolecules-10-00080]\]; the IGFR \[[@B166-biomolecules-10-00080]\], and the class A scavenger receptor \[[@B167-biomolecules-10-00080]\]. In addition, for decorin, it was suggested that several endocytic pathways can be used such as the clathrin-dependant pathway and the Tfr/recycling pathway. It also appears that endocytosis is dependent on the signaling role of EGFR, the PI-3 kinase signaling, and the lipid rafts \[[@B168-biomolecules-10-00080]\].

7. Conclusions {#sec7-biomolecules-10-00080}
==============

There is a great variability in codon usage among the SLRP coding sequences. This may impact the structure and stability of these proteoglycans. According to their codon usage, it appears that SLRPs split into two main clusters. However, it is currently unclear whether this variability in codon usage plays a functional role at all. Further investigations are required to shed light on the causal mechanisms or chain of events by which codon usage may affect the differential SLRP translation rate and how codon usage is associated with pathological conditions. In summary, current assumptions, which are not necessarily mutually exclusive, are that rare codon usage clusters in the SLRP sequences are required to increase the time available to allow for proper folding or for adequate in vivo co-translational chemical tagging on specific amino acid residues for post-translational purposes, or to cause differential sensitivity to enzymatic tRNA modifications that occur under stressed conditions.

Similarly, there is great variability of glycosylation, GAG, and sulfotyrosine patterns, as well in the SLRP fragments detected. All are subject to changes according to the related tissue, age, and pathological conditions. These heterogeneous post-translational events can contribute to various structural and biological functions of SLRPs. Accordingly, one can define SLRPs as highly versatile components of the ECM. The presence of GAGs and sulfated tyrosine domain conditions their interactions with collagens and ECM proteins, and it can be considered as a factor in ECM assembly and integrity. They are also modulating cytokine activity and availability by sequestering them and are bringing a higher level of subtlety to the cellular response ([Figure 4](#biomolecules-10-00080-f004){ref-type="fig"}). Moreover, the presence of distinct and precise GAG motifs is involved in specific functions in different cellular contexts \[[@B169-biomolecules-10-00080]\].

Concerning the SLRP catabolism, it plays a role in cell responses as well by regulating the bioavailability of the molecules under the control of SLRPs. SLRPs themselves can lose their functions and properties under this process. The catabolism can be affected by aging and impaired by pathologies such as Ehlers--Danlos syndrome, OA, RA, or Kashin--Beck disease \[[@B170-biomolecules-10-00080]\]. SLRPs form a protective coat protecting the ECM from collagenolysis induced by MMPs. Interestingly, alteration of the ECM content appears to be an early step in the progression of a pathology disrupting the ECM properties and functions and later deregulates the cell homeostasis ([Figure 4](#biomolecules-10-00080-f004){ref-type="fig"}). SLRP fragments can be soluble and circulate in biological fluid, where they might trigger a biological response in other tissues. This means that SLRPs could be actors in aging-related musculoskeletal and rheumatic diseases and could be therapeutic targets. They could also be potential soluble biomarkers that are useful for the diagnosis and prognosis of disease progression as well as predictive of therapeutic response. Indeed, numerous SLRP fragments were identified through mass spectrometry to have the potential to be unique neopeptides characterizing pathologic conditions such as cartilage degradation and OA onset \[[@B132-biomolecules-10-00080],[@B171-biomolecules-10-00080],[@B172-biomolecules-10-00080],[@B173-biomolecules-10-00080],[@B174-biomolecules-10-00080],[@B175-biomolecules-10-00080]\]. In particular, a biglycan neoepitope issued from MMP cleavage measured in rat serum is correlated with pathologies involving imbalanced ECM remodeling \[[@B123-biomolecules-10-00080]\]. These features could be tracked down to follow the initiation and development of pathologies that are hard to diagnose at an early stage.

In summary, post-translational events encompass a large number of modifications in the SLRP core proteins. They help ECM assembly and are involved in the ECM physicochemical properties and remodeling. They are also required by cells to regulate responses with higher precision. They are valuable fingerprints of the tissues and a characterizing tool that can be used as biomarkers. Here, we focused on the SLRP post-translational events and degradation in skeletal tissues; however, they exert their modulation of biological functions in other tissues as well. Unfortunately, few studies discuss their functions and take them into account when analyzing results. Given the findings summarized in this review, we conclude that their biological functions are too often underestimated, and we hope that future studies will be more careful to consider the impact of post-translational events on biological functions and include them in their design.
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![(**A**). Osteomodulin in 3D view (PDB id: 5YQ5) with PyMol showing the horseshoe shape with 13 β-sheets on the concave side and 13 α-helices on the convex side. (**B**). Osteomodulin in 3D view (PDB id: 5YQ5) with PyMol showing cystein residues (in blue) of the protein near the N-terminal (C66, C68--C78 on the left) and C-terminal end (C321--C353 on the right downstream of the ear-repeat). The secondary structure's graphical representations showing the small leucine-rich proteoglycans (SLRPs) salient features were carried out with the PyMol software (PyMOL^TM^ 2.3.1---Incentive Product Copyright Schrodinger, LLC) and using home-made Python scripts to display relevant amino acids in chosen colors.](biomolecules-10-00080-g001){#biomolecules-10-00080-f001}

![Percentage of variance explained by the PCs. Left panel: The first two components explain 60.08% and 10.53% of the variance, respectively. Right panel: Cumulative percentage of the variance explained. The first two components explain 60.08 + 10.53 = 70.6% of the variance in codon usage between SLRP family members' proteins.](biomolecules-10-00080-g002){#biomolecules-10-00080-f002}

![Biplot: scores of the 17 members of the SLRP family (in black) projected on the first two PCs (bottom and left first two PC scores), and red arrows indicate the loading vectors in the space of the codon usage frequency features (top and right axes first two PC loadings).](biomolecules-10-00080-g003){#biomolecules-10-00080-f003}

![Schematic representation of the biological functions of post-translational modifications impacted by aging and pathology development. On the left panel, GAG side chains and the tyrosine sulfate-rich domain of SLRPs help to maintain the ECM biomechanical properties and the fibrillogenesis and organize the collagen fibrils. They regulate the cell response and their homeostasis through their interaction with cytokines and modulate their accessibility. On the right panel, following an imbalanced control of the post-translational events and MMP-driven degradation, the ECM biological properties are disturbed, which impedes the bioavaibility of cytokines that are free to leave the ECM. This latter case can be prompted by a disease condition or the aging process.](biomolecules-10-00080-g004){#biomolecules-10-00080-f004}

biomolecules-10-00080-t001_Table 1

###### 

Classification of the SLRP family in five classes; BGN: Biglycan; DCN: Decorin; ASP: Asporin; ECM2: Extracellular Matrix Protein 2; ECMX: Extracellular Matrix Protein X; LUM: Lumican; KTN: Keratocan; FMOD: Fibromodulin; OMD: Osteomodulin; PRELP: Proline/arginine-rich end leucine-rich repeat protein; EPN: Epiphycan; OGN: Osteoglycin; OPTC: Opticin; CHAD: Chondroadherin; NYX: Nyctalopin; TSK: Tsukushi; PODN: Podocan; PODNL: Podocan-like protein. The N-terminal cysteine cluster is a major feature for the classification of this family. The 3D representations are resolved by X-ray diffraction and are publicly available on protein data base repositories such as Protein Data Bank (PDB: <https://www.rcsb.org/>). The 3D structures can be displayed and viewed with the PyMol software (Schrödinger LCC, version 2.1.1), illustrating the horseshoe shape with lateral asparagines (N shown in red thanks to a home-made Python script). X-Ray crystallographic analysis for the SLRP family members of class III and class IV are not yet available. The different post-translational modifications are listed by each SLRP family member. All information was cross-checked with the UniProt database \[[@B28-biomolecules-10-00080]\]. LRR: leucine-rich repeat.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Class                                  N-End Cysteine Motif                        3D Representation and PDB ID           Member                                                                                                                                                 GAG Type/Glycosylation                                                                                                                                                              Other                                 Ref.
  -------------------------------------- ------------------------------------------- -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  **I**                                  CX~3~CXCX~6~C                               ![](biomolecules-10-00080-i001.jpg)\   BGN                                                                                                                                                    Chondroitin sulfate\                                                                                                                                                                                                      \[[@B29-biomolecules-10-00080],[@B30-biomolecules-10-00080],[@B31-biomolecules-10-00080],[@B32-biomolecules-10-00080]\]
                                                                                     ID: 1XKU                                                                                                                                                                                      Dermatan sulfate\                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                   N-linked oligosaccharide\                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                   O-linked oligosaccharide                                                                                                                                                                                                  

  ![](biomolecules-10-00080-i002.jpg)\   DCN                                         Chondroitin sulfate\                   \[[@B30-biomolecules-10-00080],[@B31-biomolecules-10-00080],[@B32-biomolecules-10-00080],[@B33-biomolecules-10-00080],[@B34-biomolecules-10-00080]\]                                                                                                                                                                                                                             
  ID: 2FT3                                                                           Dermatan sulfate\                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                     N-linked oligosaccharide\                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                     O-linked oligosaccharide                                                                                                                                                                                                                                                                                                                                                                                                

                                         ASP                                         N-linked oligosaccharide\              \[[@B35-biomolecules-10-00080]\]                                                                                                                                                                                                                                                                                                                                                 
                                                                                     O-linked oligosaccharide                                                                                                                                                                                                                                                                                                                                                                                                

                                         ECM2                                        N-linked oligosaccharide\              ECM2 has a peculiarity in its motif with only 2 conserved cysteines.                                                                                   \[[@B19-biomolecules-10-00080],[@B31-biomolecules-10-00080]\]                                                                                                                                                             
                                                                                     No data on potential GAG                                                                                                                                                                                                                                                                                                                                                                                                

  ECMX                                   No data on potential GAG or glycosylation                                          \[[@B31-biomolecules-10-00080]\]                                                                                                                                                                                                                                                                                                                                                 

  **II**                                 CX~3~CXCX~9~C                                                                      LUM                                                                                                                                                    Keratan sulfate\                                                                                                                                                                    Tyrosine sulfation                    \[[@B36-biomolecules-10-00080],[@B37-biomolecules-10-00080],[@B38-biomolecules-10-00080]\]
                                                                                                                                                                                                                                                                                   Poly-lactosamine\                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                   N-linked oligosaccharide                                                                                                                                                                                                  

  KTN                                    \[[@B39-biomolecules-10-00080]\]                                                                                                                                                                                                                                                                                                                                                                                                                                    

  ![](biomolecules-10-00080-i003.jpg)\   FMOD                                        Keratan sulfate\                       Tyrosine sulfation\                                                                                                                                    \[[@B38-biomolecules-10-00080],[@B40-biomolecules-10-00080],[@B41-biomolecules-10-00080],[@B42-biomolecules-10-00080]\]                                                                                                   
  ID: 5MX0                                                                           Poly-lactosamine\                      Acidic patch                                                                                                                                                                                                                                                                                                                                                                     
                                                                                     N-linked oligosaccharide                                                                                                                                                                                                                                                                                                                                                                                                

  ![](biomolecules-10-00080-i004.jpg)\   OMD                                         Keratan sulfate\                       \[[@B38-biomolecules-10-00080],[@B43-biomolecules-10-00080],[@B44-biomolecules-10-00080],[@B45-biomolecules-10-00080]\]                                                                                                                                                                                                                                                          
  ID: 5YQ5                                                                           N-linked oligosaccharide                                                                                                                                                                                                                                                                                                                                                                                                

                                         PRELP                                       N-linked oligosaccharide               Basic patch                                                                                                                                            \[[@B46-biomolecules-10-00080],[@B47-biomolecules-10-00080]\]                                                                                                                                                             

  **III**                                CX~2~CXCX~6~C                                                                      EPN                                                                                                                                                    Chondroitin sulfate\                                                                                                                                                                LRRs with only seven repeats\         \[[@B30-biomolecules-10-00080],[@B31-biomolecules-10-00080]\]
                                                                                                                                                                                                                                                                                   Dermatan sulfate\                                                                                                                                                                   Tyrosine sulfation\                   
                                                                                                                                                                                                                                                                                   N-linked oligosaccharide\                                                                                                                                                           Acidic patch                          
                                                                                                                                                                                                                                                                                   O-linked oligosaccharide                                                                                                                                                                                                  

                                         OGN                                         Keratan sulfate\                       LRRs with only seven repeats\                                                                                                                          \[[@B31-biomolecules-10-00080],[@B48-biomolecules-10-00080],[@B49-biomolecules-10-00080],[@B50-biomolecules-10-00080],[@B51-biomolecules-10-00080],[@B52-biomolecules-10-00080]\]                                         
                                                                                     Chondroitin sulfate\                   Tyrosine sulfation                                                                                                                                                                                                                                                                                                                                                               
                                                                                     Dermatan sulfate\                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                     N-linked oligosaccharide                                                                                                                                                                                                                                                                                                                                                                                                

                                         OPTC                                        N-linked oligosaccharide\              \[[@B31-biomolecules-10-00080],[@B53-biomolecules-10-00080],[@B54-biomolecules-10-00080]\]                                                                                                                                                                                                                                                                                       
                                                                                     O-linked oligosaccharide                                                                                                                                                                                                                                                                                                                                                                                                

  **IV**                                 CX~3~CXCX~6-17~C                            ![](biomolecules-10-00080-i005.jpg)\   CHAD                                                                                                                                                   Keratan sulfate\                                                                                                                                                                                                          \[[@B31-biomolecules-10-00080],[@B55-biomolecules-10-00080]\]
                                                                                     ID: 5MX1                                                                                                                                                                                      O-linked oligosaccharide                                                                                                                                                                                                  

                                         NYX\                                        N-linked oligosaccharide               \[[@B31-biomolecules-10-00080]\]                                                                                                                                                                                                                                                                                                                                                 
                                         TSK                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **V**                                  CX~3-4~CXCX~9~C                                                                    PODN                                                                                                                                                   N-linked oligosaccharide                                                                                                                                                            High number of LRR with 20 repeats\   \[[@B9-biomolecules-10-00080],[@B56-biomolecules-10-00080],[@B57-biomolecules-10-00080]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Acidic patch                          

  PODNL                                  High number of LRR with 21 repeats          \[[@B58-biomolecules-10-00080]\]                                                                                                                                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

biomolecules-10-00080-t002_Table 2

###### 

Representation of the biased codon usage patterns of the mature mRNA transcripts among Cluster 1 and Cluster 2 of the SLRP family. Over-represented codons are colored in green and marked by a '+'; under-represented codons are colored in red and marked by a '--'.

                         Cluster 1   Cluster 2
  ---------------- ----- ----------- -----------
  **Leucine**      CUG   \+          −
                   CUC   \+          −
                   CUU   −           \+
                   CUA   −           \+
                   UUG   −           \+
                   UUA   −           \+
  **Glutamate**    GAG   \+          −
                   GAA   −           \+
  **Glutamine**    CAG   \+          −
                   CAA   −           \+
  **Lysine**       AAG   \+          −
                   AAA   −           \+
  **Aspartate**    GAC   \+          −
                   GAU   −           \+
  **Asparagine**   AAC   \+          −
                   AAU   −           \+
  **Cysteine**     UGC   \+          −
                   UGU   −           \+

biomolecules-10-00080-t003_Table 3

###### 

Specific cleavage sites among the SLRP family in the skeletal tissues.

  SLRP             Species   Cleavage Site   Protease            Technique                                           In Vivo Data                                                                          Ref
  ---------------- --------- --------------- ------------------- --------------------------------------------------- ------------------------------------------------------------------------------------- -----------------------------------
  Decorin          Human                                                                                                                                                                                   
                             S241-L242       MMP2                N-terminal sequencing                               \-                                                                                    \[[@B116-biomolecules-10-00080]\]
                             S241-L242       MMP3                N-terminal sequencing                               \-                                                                                    
                             D31-A32         MMP7                N-terminal sequencing                               \-                                                                                    
                             E274-L273       MMP7                N-terminal sequencing                               \-                                                                                    
                             S240-L241       MMP-13              N-terminal sequencing                               Comparison with WB on cartilage                                                       \[[@B119-biomolecules-10-00080]\]
                   Bovine                                                                                                                                                                                  
                             M200-K201       \-                  N-terminal sequencing                               Extracted from fresh matrix tendon                                                    \[[@B129-biomolecules-10-00080]\]
                             A209-D210       \-                                                                                                                                                            
                             Q218-G219       \-                  Extracted from medium of cultured tendon                                                                                                  
  Biglycan         Human                                                                                                                                                                                   
                             G177-V178       MMP-13              N-terminal sequencing                               Comparison with WB on cartilage                                                       \[[@B119-biomolecules-10-00080]\]
                   Bovine                                                                                                                                                                                  
                             N187-C188       ADAMTS-4 ADAMTS-5   N-terminal sequencing                               Comparison with WB on cartilage                                                       \[[@B124-biomolecules-10-00080]\]
  Fibromodulin     Human                                                                                                                                                                                   
                             Y63-T64         MMP-13              Data not shown                                      Data not shown                                                                        \[[@B113-biomolecules-10-00080]\]
                   Bovine                                                                                                                                                                                  
                             Y63-A64         MMP-13              Mass spectrometry                                   Extracted from cartilage explant                                                      \[[@B113-biomolecules-10-00080]\]
  Opticin          Human                                                                                                                                                                                   
                             T87-S88         MMP-2 MMP-7         N-terminal sequencing                               Comparison with WB on cartilage                                                       \[[@B122-biomolecules-10-00080]\]
                             E443-L444       MMP-2 MMP-7                                                                                                                                                   
                             G114-L115       MMP-2 MMP-7         Prediction from \[[@B120-biomolecules-10-00080]\]                                                                                         
                             A20-S21         MMP-7               N-terminal sequencing                                                                                                                     
                             E32-Q33         MMP-7                                                                                                                                                         
                   Bovine                                                                                                                                                                                  
                             G104-L105       MMP-13              N-terminal sequencing                               Comparison with WB on human cartilage; IHC on human cartilage and synovial membrane   \[[@B120-biomolecules-10-00080]\]
                             P109-A110       MMP-13                                                                                                                                                        
  Chondroadherin   Human                                                                                                                                                                                   
                             I80-Y81         HTRA1               Mass spectrometry                                   Comparison with WB on discs tissue                                                    \[[@B127-biomolecules-10-00080]\]
